Premium
Clinical study of daunomycin (NSC‐82151) in children with acute leukemia
Author(s) -
Holton Charlene P.,
Lonsdale Chairman Derrick,
Nora Audrey H.,
Thurman William G.,
Vietti Teresa J.
Publication year - 1968
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(196811)22:5<1014::aid-cncr2820220517>3.0.co;2-f
Subject(s) - medicine , prednisone , cytopenia , leukopenia , leukemia , toxicity , gastroenterology , chemotherapy , acute leukemia , bone marrow
Thirty‐nine children with advanced leukemia, resistant to conventional chemotherapy, were treated with daunomycin. Seven patients (18%) achieved partial or complete marrow remissions within a median time of 17 days. Five of the seven children who responded received prednisone concurrently. The remissions lasted only 21–37 days. Limiting toxicity included leukopenia, thrombo‐cytopenia, and oral ulcerations. No renal, hepatic, or cardiac toxicity was noted. It is concluded that daunomycin alone has low‐grade activity for induction of remission in children with advanced acute leukemia and that combination with prednisone may enhance the response rate.